Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (13)	9/30/1999 4:59:00 PM
From: KS	Read Replies (1) \| Respond to of 411

Type of Offering: Follow-On Offering Proposed Symbol: CVTX Type of Security: Common Stock Expected Size of Offering: 4,000,000 Expected Price Range: Set at time of pricing Expected Pricing Date: 1999/10/05 Brief Description of Offering Company: CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. Lead Manager: Donaldson, Lufkin & Jenrette ******** Any comments?

To: scaram(o)uche who wrote (13)	7/12/2002 10:33:49 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 411

>> DTI recently announced an agreement with Fujisawa Healthcare, Inc. to develop an injectable form of DTI-0009. DTI will conduct the Phase I clinical trial while Fujisawa will be responsible for the remaining clinical development and commercialization of this product. Fujisawa has exclusive rights to the injectable product in the United States and Canada. DTI retains international rights for the injectable formulation and worldwide rights for the oral formulation. << Update......... Aderis Pharmaceutical, which has an S-1 out....... DTI-0009 is an adenosine A\\1\\ agonist designed to control heart rate in atrial fibrillation by slowing conduction through the atrioventricular node. Atrial fibrillation is the most common of the cardiac arrhythmias, or abnormal heart rhythms, and affects approximately six million patients worldwide. DTI-0009 is being developed as both an oral formulation for chronic and an intravenous formulation for acute therapy. Fujisawa Healthcare has the exclusive, clinical development and commercialization rights, in the United States and Canada, for the intravenous formulation of DTI-0009. The intravenous formulation of DTI-0009 is in Phase II clinical trials in the United States. DTI-0017 is an adenosine A\\1\\ antagonist designed to treat edema typically associated with congestive heart failure. Approximately 4.7 million people in the United States suffer from congestive heart failure. DTI-0017 is being developed as both an oral formulation for chronic and an intravenous formulation for acute therapy. Our own studies and other published research suggest that adenosine A\\1\\ antagonists, such as DTI-0017, appear to act at a different site in the kidney from most diuretics, does not affect potassium balance, appear to prevent the decreased renal function seen with some other diuretics and may prevent the development of resistance to the diuretic effect occurring with some other agents. We have concluded our first Phase I clinical trial and are currently reformulating the product candidate and conducting additional animal testing. and from the S-1, clarifying everything....... We were incorporated as Discovery Therapeutics, Inc. in Delaware in 1994 and changed our name to Aderis Pharmaceuticals, Inc. in January 2002. Our principal executive offices are located at 85 Main Street, Hopkinton, Massachusetts 01748